Influence of artificial intelligence on the performance of endosonographers in detection of solid pancreatic tumors: a tandem randomized video study.

EndoscopyAug 19, 2026 (epub)
Clinical ResearchGastroenterology

Julieta Montanelli, Leonardo Sosa-Valencia, Peter Vilmann et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the impact of an AI-based software system on endosonographers' performance in detecting solid pancreatic tumors (SPTs) using curated EUS videos. Among 57 endosonographers, diagnostic accuracy improved from 70.8% without AI to 77.1% with AI assistance (P < 0.001), particularly for high-complexity clips.

Key findings

  • Diagnostic accuracy improved from 70.8% without AI to 77.1% with AI (P < 0.001).
  • Stand-alone AI accuracy was 92.3%.
  • AI assistance significantly increased diagnostic confidence (P < 0.001).
  • No significant difference in AI effect was found between experience levels.

Why it matters

The integration of AI in endoscopic ultrasound may enhance diagnostic accuracy and confidence in detecting challenging pancreatic tumors, potentially leading to earlier and more accurate diagnoses.

Source

PubMed · PMID 42617651

Published in Endoscopy. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.